on Lobe Sciences Ltd. (CVE:LOBE)
Lobe Sciences Appoints New CFO Amid Strategic Growth
Lobe Sciences Ltd., a clinical-stage biopharmaceutical company, announced the appointment of Dr. David Kideckel as Chief Financial Officer, effective September 1, 2026. Dr. Kideckel brings close to two decades of expertise in the life sciences, capital markets, and corporate advisory sectors.
Dr. Frederick D. Sancilio, Chairman and CEO of Lobe, highlighted Dr. Kideckel's unique blend of scientific expertise and industry experience. This move aims to support the advancement of L-130, a non-hallucinogenic therapeutic for chronic cluster headaches. Dr. Kideckel expressed enthusiasm about strengthening Lobe's financial strategy and advancing its clinical programs.
The current CFO, Mirza Rahimani, will transition to Vice President of Finance, ensuring continuity in financial operations. This strategic leadership expansion is set to bolster Lobe's strategic growth and development endeavors.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Lobe Sciences Ltd. news